Emily Field
Stock Analyst at Barclays
(3.24)
# 2,486
Out of 5,118 analysts
735
Total ratings
45.9%
Success rate
2.2%
Average return
Main Sectors:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Reiterated: Buy | $110 | $53.69 | +104.88% | 10 | Nov 5, 2026 | |
| PFE Pfizer | Reiterated: Sell | $25 | $29.39 | -14.94% | 7 | Nov 3, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $75 | $62.14 | +20.70% | 10 | Oct 29, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,400 | $1,354.00 | +3.40% | 36 | Oct 29, 2026 | |
| BIIB Biogen | Reiterated: Hold | $200 → $230 | $248.35 | -7.39% | 8 | Oct 28, 2026 | |
| GILD Gilead Sciences | Reiterated: Hold | $145 | $166.89 | -13.12% | 6 | Oct 28, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $180 | $146.73 | +22.67% | 16 | Oct 28, 2026 | |
| AMGN Amgen | Reiterated: Hold | $400 | $460.42 | -13.12% | 11 | Oct 26, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $300 → $325 | $291.31 | +11.57% | 12 | Oct 21, 2026 | |
| GSK GSK plc | Downgraded: Sell | n/a | $50.33 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $162.55 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $59.37 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $47.04 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 275.00 | CHF 390.30 | n/a | 59 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €115.00 → €105.00 | €83.74 | n/a | 37 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 1,450p | 1,890p | n/a | 126 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 46.50 → CHF 55.00 | CHF 83.78 | n/a | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 14,000p | 13,930p | n/a | 78 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €22.00 | €29.62 | n/a | 32 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | CHF 90.00 | CHF 133.08 | n/a | 44 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €25.00 | €55.58 | n/a | 59 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 2,000p | 1,650p | n/a | 61 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €195.00 | €148.75 | n/a | 74 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €8.00 → €9.00 | €11.25 | n/a | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €75.00 | €158.70 | n/a | 22 | Nov 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $141 → $125 | $33.45 | n/a | 7 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52.71 | $23.16 | n/a | 1 | Aug 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $8.43 | n/a | 2 | Jun 1, 2018 |
Cytokinetics
Nov 5, 2026
Reiterated: Buy
Price Target: $110
Current: $53.69
Upside: +104.88%
Pfizer
Nov 3, 2026
Reiterated: Sell
Price Target: $25
Current: $29.39
Upside: -14.94%
Bristol-Myers Squibb Company
Oct 29, 2026
Reiterated: Buy
Price Target: $75
Current: $62.14
Upside: +20.70%
Eli Lilly and Company
Oct 29, 2026
Reiterated: Buy
Price Target: $1,400
Current: $1,354.00
Upside: +3.40%
Biogen
Oct 28, 2026
Reiterated: Hold
Price Target: $200 → $230
Current: $248.35
Upside: -7.39%
Gilead Sciences
Oct 28, 2026
Reiterated: Hold
Price Target: $145
Current: $166.89
Upside: -13.12%
Merck & Co.
Oct 28, 2026
Reiterated: Buy
Price Target: $180
Current: $146.73
Upside: +22.67%
Amgen
Oct 26, 2026
Reiterated: Hold
Price Target: $400
Current: $460.42
Upside: -13.12%
AbbVie
Oct 21, 2026
Reiterated: Buy
Price Target: $300 → $325
Current: $291.31
Upside: +11.57%
GSK plc
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $50.33
Upside: -
Jan 6, 2026
Upgraded: Hold
Price Target: n/a
Current: $162.55
Upside: -
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $59.37
Upside: -
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $47.04
Upside: -
Sep 24, 2025
Reiterated: Hold
Price Target: CHF 275.00
Current: CHF 390.30
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: €115.00 → €105.00
Current: €83.74
Upside: n/a
Aug 12, 2025
Reiterated: Hold
Price Target: 1,450p
Current: 1,890p
Upside: n/a
Aug 8, 2025
Reiterated: Buy
Price Target: CHF 46.50 → CHF 55.00
Current: CHF 83.78
Upside: n/a
Jul 30, 2025
Reiterated: Buy
Price Target: 14,000p
Current: 13,930p
Upside: n/a
Jul 29, 2025
Reiterated: Sell
Price Target: €22.00
Current: €29.62
Upside: n/a
Jul 21, 2025
Reiterated: Sell
Price Target: CHF 90.00
Current: CHF 133.08
Upside: n/a
Jun 27, 2025
Reiterated: Hold
Price Target: €25.00
Current: €55.58
Upside: n/a
Apr 25, 2025
Reiterated: Hold
Price Target: 2,000p
Current: 1,650p
Upside: n/a
Oct 29, 2024
Reiterated: Buy
Price Target: €195.00
Current: €148.75
Upside: n/a
Nov 21, 2022
Reiterated: Sell
Price Target: €8.00 → €9.00
Current: €11.25
Upside: n/a
Nov 25, 2021
Reiterated: Sell
Price Target: €75.00
Current: €158.70
Upside: n/a
Jan 19, 2021
Reiterated: Hold
Price Target: $141 → $125
Current: $33.45
Upside: n/a
Aug 28, 2020
Reiterated: Hold
Price Target: $52.71
Current: $23.16
Upside: n/a
Jun 1, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $8.43
Upside: n/a